Related references
Note: Only part of the references are listed.Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2021)
The SIRPα-CD47 immune checkpoint in NK cells
Tobias Deuse et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Filippo Veglia et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Robyn J. Puro et al.
MOLECULAR CANCER THERAPEUTICS (2020)
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
Marisa O. Peluso et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The clearance of dead cells by efferocytosis
Emilio Boada-Romero et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance
Vanessa Gauttier et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα don't eat me immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation
Mark A. J. M. Hendriks et al.
ONCOIMMUNOLOGY (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Sreyan Chowdhury et al.
NATURE MEDICINE (2019)
TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties
Zhen Meng et al.
BLOOD (2019)
Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
Gregor Hutter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Lipoprotein Lipase Deficiency Impairs Bone Marrow Myelopoiesis and Reduces Circulating Monocyte Levels
Chuchun L. Chang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy
Ryuma Tokunaga et al.
CANCER TREATMENT REVIEWS (2018)
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
Sabine Hoves et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Vanessa Buatois et al.
MOLECULAR CANCER THERAPEUTICS (2018)
ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
Steven E. Kauder et al.
PLOS ONE (2018)
Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
Xiaojuan Liu et al.
CELL REPORTS (2018)
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
Elie Dheilly et al.
ANTIBODIES (2018)
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Gregory L. Beatty et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Cellular metabolism of tumor-associated macrophages - functional impact and consequences
Katrin Rabold et al.
FEBS LETTERS (2017)
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling
Meng Michelle Xu et al.
IMMUNITY (2017)
Tricking the balance: NK cells in anti-cancer immunity
Jens Pahl et al.
IMMUNOBIOLOGY (2017)
Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
Elie Dheilly et al.
MOLECULAR THERAPY (2017)
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Jennifer L. Guerriero et al.
NATURE (2017)
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Nan Guo Ring et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets
Gloria H. Y. Lin et al.
PLOS ONE (2017)
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Jonathan T. Sockolosky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Anna-Maria Georgoudaki et al.
CELL REPORTS (2016)
Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo
Michael Zhang et al.
PLOS ONE (2016)
The role of myeloid cells in cancer therapies
Camilla Engblom et al.
NATURE REVIEWS CANCER (2016)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu et al.
PLOS ONE (2015)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Dendritic Cell Tumor Killing Activity and Its Potential Applications in Cancer Immunotherapy
Neale Hanke et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2013)
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
Diane Tseng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Dendritic Cells in the Cancer Microenvironment
Yang Ma et al.
JOURNAL OF CANCER (2013)
Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function
Katharine D. Grugan et al.
JOURNAL OF IMMUNOLOGY (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Macrophages prevent human red blood cell reconstitution in immunodeficient mice
Zheng Hu et al.
BLOOD (2011)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
M2 Macrophages phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
Marzia Leidi et al.
JOURNAL OF IMMUNOLOGY (2009)
Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells
Katsuto Takenaka et al.
NATURE IMMUNOLOGY (2007)
NOD/SCID/γcnull mouse:: an excellent recipient mouse model for engraftment of human cells
M Ito et al.
BLOOD (2002)
Share Paper
